Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREND-FL: Tafasitamab and Rituximab in Newly Diagnosed Follicular Lymphoma
NCT07731789Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Oct 2026
- Primary completion
- Oct 2030
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab in follicular lymphoma (FL), sponsored by University of Washington. Started Oct 2026; status: recruiting.
02
Drugs
tafasitamab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07731789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07731789.